A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Condition:   HOCM, Hypertrophic Obstructive Cardiomyopathy Interventions:   Drug: Mavacamten;   Drug: Placebo Sponsor:   MyoKardia, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials